Vision 2020: looking back and thinking forward on The Lancet Oncology Commissions - 02/09/20
Doi : 10.1016/S1470-2045(20)30481-2
Mary K Gospodarowicz a 
, David A Jaffray b, Felicia M Knaul c, d, e
, David A Jaffray b, Felicia M Knaul c, d, e a Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada
b MD Anderson Cancer Center, Houston, TX, USA
c Institute for Advanced Study of the Americas, and Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL, USA
d Tómatelo a Pecho, Mexico City, Mexico
e Mexican Health Foundation, Mexico City, Mexico
Il testo completo di questo articolo è disponibile in PDF.
© 2020
Elsevier Ltd. Tutti i diritti riservati.
Vol 21 - N° 9
P. 1144-1146 - settembre 2020 Ritorno al numero
Articolo precedente
- Patients with cancer hit hard by deadly explosions in Beirut
- Elizabeth Gourd
- Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study
- Diane Goéré, Olivier Glehen, François Quenet, Jean-Marc Guilloit, Jean-Marc Bereder, Gérard Lorimier, Emilie Thibaudeau, Laurent Ghouti, Amandine Pinto, Jean-Jacques Tuech, Reza Kianmanesh, Michel Carretier, Frédéric Marchal, Catherine Arvieux, Cécile Brigand, Pierre Meeus, Patrick Rat, Sylvaine Durand-Fontanier, Pascale Mariani, Zaher Lakkis, Valeria Loi, Nicolas Pirro, Charles Sabbagh, Matthieu Texier, Dominique Elias, BIG-RENAPE group, M Ducreux, D Malka, V Boige, E Benhamou
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?